AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
AbbVie Soars 3.66% on Q1 Earnings Beat
Generated by AI AgentAinvest Movers Radar
Friday, Apr 25, 2025 8:02 am ET1min read
AbbVie's stock rose 3.66% in pre-market trading on April 25, 2025, driven by strong first-quarter financial results.
AbbVie reported first-quarter 2025 revenue of $13.34 billion, surpassing market expectations of $12.94 billion. This represents a 4% year-over-year increase, with the company's new immunology drugs, Skyrizi and Rinvoq, contributing significantly to this growth. Skyrizi, in particular, has shown remarkable performance, with its fourth-quarter sales exceeding those of
, the company's former flagship product.Despite the decline in Humira sales due to biosimilar competition, AbbVie's overall performance remains robust. The company has also raised its full-year 2025 adjusted earnings per share (EPS) forecast to a range of $12.09 to $12.29, up from the previous estimate of $11.99. This adjustment reflects the strong sales of newer drugs and the company's strategic focus on innovation and growth.
Looking ahead,
is well-positioned to continue its growth trajectory. The company's pipeline includes several promising new drugs, such as Vylev for Parkinson's disease, which is expected to achieve peak sales of over $20 billion. Additionally, AbbVie's strategic investments in research and development are likely to yield further breakthroughs, ensuring sustained growth in the coming years.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
Dynavax (DVAX) Shares Plunge 1.70% Amid Regulatory and Legal Risks in Sanofi Deal
Dec.24 2025
Intuitive Machines Stock Plunges 12.04% on CEO Share Sale Q3 Loss Acquisition Risks
Dec.24 2025
Repare Therapeutics Dives 2.25% to 12-Month Low Amid Strategic Uncertainty *Key drivers: Pending XenoTherapeutics bid, Gilead asset sale reshape investor sentiment*
Dec.24 2025
Reviva Pharmaceuticals (RVPH) Plunge 55.93% as FDA Demands Additional Trial for Schizophrenia Drug
Dec.24 2025
Fermi Shares Plunge 7.21% to Monthly Low on AICA Termination, Legal Scrutiny
Dec.24 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet